4.2119

3.74% 0.1519

Pre-market: 4.25 0.0381 +0.90%

Turn Therapeutics Inc (TTRX)

Overview News Price History Discussions Forecast

Turn Therapeutics Inc stock is traded at $4.2119, with a volume of 72,447. It is up +3.74% in the last 24 hours and down -2.62% over the past month. Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Previous Close:

$4.06

Open:

$3.85

24h Volume:

72,447

Relative Volume:

0.19

Market Cap:

$124.02M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+23.88%

1M Performance:

-2.62%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$3.84

$4.35

1-Week Range:

$3.41

$4.35

52-Week Range:

$2.5701

$26.50

Turn Therapeutics Inc Stock (TTRX) Company Profile

Name

Turn Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

(818) 564-4011

Address

250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TTRX's Discussions on Twitter

Compare TTRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TTRX Turn Therapeutics Inc	4.2119	119.55M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Turn Therapeutics Inc Stock (TTRX) Latest News

Nov 25, 2025

Arthur Golden Increases Stake in Turn Therapeutics Inc with Rece - GuruFocus

Nov 25, 2025

Golden Arthur F buys Turn Therapeutics shares worth $33945 By Investing.com - Investing.com Nigeria

Nov 25, 2025

Insider Buying: Arthur Golden Acquires Additional Shares of Turn Therapeutics Inc (TTRX) - GuruFocus

Nov 24, 2025

Turn Therapeutics Director Arthur F. Golden Acquires 20,532 Shares - TradingView

Nov 24, 2025

Dir Golden Buys 20,532 ($58.9K) Of Turn Therapeutics Inc [TTRX] - TradingView

Nov 24, 2025

[Form 4] Turn Therapeutics Inc. Insider Trading Activity - Stock Titan

Nov 24, 2025

Turn Therapeutics Inc. Common Stock trading resumes - MSN

Nov 24, 2025

Nov 18, 2025

Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 By Investing.com - Investing.com Nigeria

Nov 18, 2025

Nov 17, 2025

Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 - Investing.com

Nov 17, 2025

Nov 15, 2025

Turn Therapeutics (TTRX) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

Nov 15, 2025

Nov 14, 2025

Turn Therapeutics’ GX-03 Recognized for Dermatology Innovation - MSN

Nov 14, 2025

Nov 13, 2025

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times

Nov 13, 2025

Nov 12, 2025

Turn Therapeutics GX-03 Technology Named as One of Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment by Patient Care Online Magazine - MarketScreener

Nov 12, 2025

Nov 11, 2025

Turn Therapeutics (Nasdaq: TTRX) features Dr. Robert Redfield on trust in science - Stock Titan

Nov 11, 2025

Turn Therapeutics’ GX-03 Technology Named as One of 'Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - The Manila Times

Nov 11, 2025

Turn (NASDAQ: TTRX) named among five novel eczema mechanisms by Patient Care Online - Stock Titan

Nov 11, 2025

Nov 05, 2025

Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications - Investing.com Australia

Nov 05, 2025

Nov 04, 2025

Turn Therapeutics Appoints New VP of Communications - TipRanks

Nov 04, 2025

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications - The Globe and Mail

Nov 04, 2025

Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications By Investing.com - Investing.com South Africa

Nov 04, 2025

Turn Therapeutics Appoints Veteran Capital Markets - GlobeNewswire

Nov 04, 2025

Turn Therapeutics (NASDAQ: TTRX) names Andrew Scott VP of Corporate Communications; 30 years - Stock Titan

Nov 04, 2025

Turn Therapeutics launches webinar series for shareholder engagement - MSN

Nov 04, 2025

Nov 03, 2025